EWA
MIST icon

Exit Wealth Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Exit Wealth Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4K Buy
22,692
+7,692
+51% +$12.3K 0.01% 149
2026
Q1 		$17.9K Buy
+15,000
New +$26.3K 0.01% 130

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Exit Wealth Advisors's MIST Position: Q2 2026 in Review

Exit Wealth Advisors increased its Milestone Pharmaceuticals (MIST) stake by 51% in Q2 2026, buying an estimated $12.3K and bringing the position to 22,692 shares worth $30.4K. The position accounts for 0.01% of the portfolio, ranked #149.

Exit Wealth Advisors first reported a position in MIST in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Exit Wealth Advisors held 22,692 shares of Milestone Pharmaceuticals worth $30.4K as of Q2 2026.
  • Exit Wealth Advisors bought 7,692 Milestone Pharmaceuticals shares in Q2 2026, an estimated $12.3K.
  • Milestone Pharmaceuticals made up 0.01% of Exit Wealth Advisors's portfolio in Q2 2026, its #149 holding.
  • Exit Wealth Advisors first reported a position in Milestone Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Exit Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.